Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36

Parasitology International

Volumn 59, Issue 3, 2010, Pages 380-386

  Horii, Toshihiro ^a   Shirai, Hiroki ^b   Jie, Li ^a   Ishii, Ken J ^a,c   Palacpac, Nirianne Q ^a   Tougan, Takahiro ^a   Hato, Mariko ^d   Ohta, Nobuo ^d   Bobogare, Albino ^e   Arakaki, Nana ^f   Matsumoto, Yoshitsugu ^f   Namazue, Junko ^b   Ishikawa, Toyokazu ^b   Ueda, Shigeharu ^b   Takahashi, Michiaki ^b  

^a OSAKA UNIVERSITY   (Japan)

^b Osaka University   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e Solomon Islands Ministry of Health and Medical Services   (Solomon Islands)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

Epidemiology; Malaria; Serine repeat antigen (SERA); Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; PARASITE ANTIGEN; RECOMBINANT PROTEIN; SERINE REPEAT ANTIGEN 5; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CHIMPANZEE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNOGENICITY; JAPANESE; MALARIA; MALARIA FALCIPARUM; MALE; NONHUMAN; PARASITEMIA; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROEPIDEMIOLOGY; SINGLE BLIND PROCEDURE; SQUIRREL MONKEY; VACCINATION; VACCINE PRODUCTION;

ANIMALIA; PAN; PLASMODIUM FALCIPARUM; PRIMATES; SAIMIRI;

EID: 77955329010     PISSN: 13835769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parint.2010.05.002     Document Type: Article

References (30)

1. Doolan D.L., Dobano C., Baird J.K. Acquired immunity to malaria. Clin Microbiol Rev 2009, 22:13-36.
2. Richards J.S., Beeson J.G. The future for blood-stage vaccines against malaria. Immunol Cell Biol 2009, 87:377-390.
3. Delplace P., Fortier B., Tronchin G., Dubremetz J.F., Vernes A. Localization, biosynthesis, processing and isolation of a major 126kDa antigen of the parasitophorous vacuole of Plasmodium falciparum. Mol Biochem Parasitol 1987, 23:193-203.
4. Bzik D.J., Li W.B., Horii T., Inselburg J. Amino acid sequence of the serine-repeat antigen (SERA) of Plasmodium falciparum determined from cloned cDNA. Mol Biochem Parasitol 1988, 30:279-288.
5. Fox B.A., Bzik D.J. Analysis of stage specific transcripts of the Plasmodium falciparum serine repeat antigen (SERA) gene and transcription from the SERA locus. Mol Biochem Parasitol 1994, 68:133-144.
6. Gardner M.J., Tettelin H., Carucci D.J., Cummings L.M., Aravind L., Koonin E.V., et al. Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science 1998, 282:1126-1132. Erratum in Science 1998;282:1827.
7. Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419:498-511.
8. Arisue N., Hirai M., Arai M., Matsuoka H., Horii T. Phylogeny and evolution of the SERA multigene family in the genus Plasmodium. J Mol Evol 2007, 65:82-91.
9. Knapp B., Hundt E., Nau U., Kupper H.A. Molecular cloning, genomic structure and localization in a blood stage antigen of Plasmodium falciparum characterized by a serine stretch. Mol Biochem Parasitol 1989, 32:73-83.
10. Delplace P., Dubremetz J.F., Fortier B., Vernes A. A 50 kilodalton exoantigen specific to the merozoite release-reinvasion stage of Plasmodium falciparum. Mol Biochem Parasitol 1985, 17:239-251.
11. Debrabant A., Maes P., Delplace P., Dubremetz J.F., Tartar A., Camus D. Intramolecular mapping of Plasmodium falciparum P126 proteolytic fragments by N-terminal amino acid sequencing. Mol Biochem Parasitol 1992, 53:89-95.
12. Li J., Mitamura T., Fox B.A., Bzik D.J., Horii T. Differential localization of processed fragments of Plasmodium falciparum serine repeat antigen and further processing of its N-terminal 47kDa fragment. Parasitol Int 2002, 53:89-95.
13. Li J., Matsuoka H., Mitamura T., Horii T. Characterization of proteases involved in the processing of Plasmodium falciparum serine repeat antigen (SERA). Mol Biochem Parasitol 2002, 120:177-186.
14. Pang X.L., Mitamura T., Horii T. Antibodies reactive with the N-terminal domain of Plasmodium falciparum serine repeat antigen inhibit cell proliferation by agglutinating merozoites and schizonts. Infect Immun 1999, 67:1821-1827.
15. Sugiyama T., Suzue K., Okamoto M., Inselburg J., Tai K., Horii T. Production of recombinant SERA proteins of Plasmodium falciparum in Escherichia coli by using synthetic genes. Vaccine 1996, 14:1069-1076.
16. Fox B.A., Xing-Li P., Suzue K., Horii T., Bzik D.J. Plasmodium falciparum: an epitope within a highly conserved region of the 47-kDa amino-terminal domain of the serine repeat antigen is a target of parasite-inhibitory antibodies. Exp Parasitol 1997, 85:121-134.
17. Pang X.L., Horii T. Complement-mediated killing of Plasmodium falciparum erythrocytic schizonts with antibodies to the recombinant serine repeat antigen (SERA). Vaccine 1998, 16:1299-1305.
18. Inselburg J., Bzik D.J., Li W.B., Green K.M., Kansopon J., Hahm B.K., et al. Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum. Infect Immun 1991, 61:1247-1250.
19. Inselburg J., Bathurst I.C., Kansopon J., Barchfeld G.L., Barr P.J., Rossan R.N. Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum: adjuvant effects on induction of protective immunity. Infect Immun 1993, 61:2041-2047.
20. Inselburg J., Bathurst I.C., Kansopon J., Barr P.J., Rossan R. Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum: further studies using SERA1 and MF75.2 adjuvant. Infect Immun 1993, 61:2048-2052.
21. Suzue K., Ito M., Matsumoto Y., Tanioka Y., Horii T. Protective immunity induced in squirrel monkeys with recombinant serine repeat antigen (SERA) of Plasmodium falciparum. Parasitol Int 1997, 46:17-25.
22. Okech B.A., Nalunkuma A., Okello D., Pang X.L., Suzue K., Li J., et al. Natural human immunoglobulin G subclass responses to Plasmodium falciparum serine repeat antigen in Uganda. Am J Trop Med Hyg 2001, 65:912-917.
23. Aoki S., Li J., Itagaki S., Okech B.A., Egwang T.G., Matsuoka H., et al. Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth. J Biol Chem 2002, 277:47533-47540.
24. Tolle R., Früh K., Doumbo O., Koita O., N'Diaye M., Fischer A., et al. A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections. Infect Immun 1993, 61(1):40-47.
25. Horii T., Matsumoto Y., Ohta N. Development of SE36 malaria vaccine targeting at Achilles heel antigen of Plasmodium falciparum [Japanese]. Cell Technol 2004, 23:785-790.
26. Horii T. Malaria researches in Japan [Japanese]. Jpn Sci Mon 2007, 60:217-223.
27. Horii T. Malaria Vaccine [Japanese]. Nippon Rinsho 2008, 66:1990-1998.
28. Horii T. Made in Japan; Malaria Vaccine Development [Japanese]. Jpn J Clin Pharmacol Ther 2007, 38:413-415.
29. Horii T. Malaria Vaccine [Japanese]. Clin Immunol Allergy 2008, 50:525-532.
30. Horii T. Development of Malaria Vaccine made in Japan [Japanese]. Infect Agents Surveill Rep 2007, 28:10-12.